Drug Topics

JUNE 10, 2025

Enflonsia provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season with the same dose regardless of weight,” Dean Y Li, president of Merck Research Laboratories, said in a release.

FDA

Drug Topics

JULY 10, 2025

Merck has been at the forefront of HIV research for more than 35 years and we are pleased to continue our work to innovate and deliver new options that aim to meet the needs of the HIV community,” Eliav Barr, senior vice president, head of global clinical development and chief medical officer at Merck Research Laboratories, said in a release.

FDA

pharmaphorum

JUNE 30, 2022

The exploratory research phase for DSP-1181 was less than a year, compared to the average of five years using traditional drug design processes, according to the two developers. However, most novel active compounds identified with the help of AI are still in discovery or preclinical stages of development.

Research Laboratories

pharmaphorum

JULY 13, 2022

Merck – known as MSD outside the US and Canada – is paying $290 million upfront for global co-development and co-marketing rights to ODM-208, a steroid synthesis inhibitor, as well as follow-up compounds in the same class. Further financial terms have not been disclosed.

Research Laboratories

European Pharmaceutical Review

JANUARY 16, 2023

MALDI-TOF works on the basis of the ionisation of chemical compounds and measurements of their mass to charge (m/z) ratio. Prior to November 2013 he worked for Merck Research Laboratories in Summit, New Jersey as the Senior Principal Scientist in early phase drug development.

Vaccines